Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.

Tian J, Raffa FA, Dai M, Moamer A, Khadang B, Hachim IY, Bakdounes K, Ali S, Jean-Claude B, Lebrun JJ.

Br J Cancer. 2018 Nov 28. doi: 10.1038/s41416-018-0287-3. [Epub ahead of print]

PMID:
30482914
2.

Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule.

Rupp M, Mouhri ZS, Williams C, Jean-Claude BJ.

Oncotarget. 2018 Oct 12;9(80):35041-35055. doi: 10.18632/oncotarget.25120. eCollection 2018 Oct 12.

3.

Examination of VDR/RXR/DRIP205 Interaction, Intranuclear Localization, and DNA Binding in Ras-Transformed Keratinocytes and Its Implication for Designing Optimal Vitamin D Therapy in Cancer.

Jusu S, Presley JF, Williams C, Das SK, Jean-Claude B, Kremer R.

Endocrinology. 2018 Mar 1;159(3):1303-1327. doi: 10.1210/en.2017-03098.

PMID:
29300860
4.

Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site.

Chatterjee A, Serban M, Abdulkarim B, Panet-Raymond V, Souhami L, Shenouda G, Sabri S, Jean-Claude B, Seuntjens J.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.

PMID:
28870791
5.
7.

Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.

Goodfellow E, Senhaji Mouhri Z, Williams C, Jean-Claude BJ.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):688-694. doi: 10.1016/j.bmcl.2016.09.054. Epub 2016 Sep 22.

PMID:
28003142
8.

Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.

Patyka M, Sharifi Z, Petrecca K, Mansure J, Jean-Claude B, Sabri S.

Oncotarget. 2016 Sep 13;7(37):60245-60269. doi: 10.18632/oncotarget.11197.

9.

Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.

Tedeschi AL, Eslami Z, Garoufalis E, Saleh RR, Omeroglu A, Altinel G, Ait-Tihyaty M, Jean-Claude B, Mihalcioiu C.

Onco Targets Ther. 2015 Apr 21;8:911-9. doi: 10.2147/OTT.S71089. eCollection 2015.

10.

ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model.

Heravi M, Kumala S, Rachid Z, Jean-Claude BJ, Radzioch D, Muanza TM.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):399-406. doi: 10.1016/j.ijrobp.2015.01.026. Epub 2015 Mar 27.

PMID:
25823448
11.

Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.

Rao S, Larroque-Lombard AL, Peyrard L, Thauvin C, Rachid Z, Williams C, Jean-Claude BJ.

PLoS One. 2015 Feb 6;10(2):e0117215. doi: 10.1371/journal.pone.0117215. eCollection 2015.

12.

Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile.

Huang Y, Rachid Z, Peyrard L, Senhaji Mouhri Z, Williams C, Jean-Claude BJ.

Chem Biol Drug Des. 2015 Feb;85(2):153-62. doi: 10.1111/cbdd.12402. Epub 2014 Sep 25.

PMID:
25092264
13.

ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.

Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ.

Invest New Drugs. 2013 Dec;31(6):1409-23.

PMID:
23959266
14.

Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor.

Larroque-Lombard AL, Ning N, Rao S, Lauwagie S, Halaoui R, Coudray L, Huang Y, Jean-Claude BJ.

Chem Biol Drug Des. 2012 Dec;80(6):981-91. doi: 10.1111/cbdd.12043.

PMID:
22943437
15.
16.

Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.

Al-Safadi S, Domarkas J, Han Y, Brahimi F, Jean-Claude BJ.

Anticancer Drugs. 2012 Jun;23(5):483-93. doi: 10.1097/CAD.0b013e328351c101.

PMID:
22421369
17.

"Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.

Fang Y, Qiu Q, Domarkas J, Larroque-Lombard AL, Rao S, Rachid Z, Gibbs BF, Gao X, Jean-Claude BJ.

Prostate. 2012 Sep 1;72(12):1273-85. doi: 10.1002/pros.22475. Epub 2012 Jan 30.

PMID:
22290742
18.

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.

Ait-Tihyaty M, Rachid Z, Mihalcioiu C, Jean-Claude BJ.

Breast Cancer Res Treat. 2012 May;133(1):217-26. doi: 10.1007/s10549-011-1756-z. Epub 2011 Sep 14.

PMID:
21915635
19.

A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity.

Golabi N, Brahimi F, Huang Y, Rachid Z, Qiu Q, Larroque-Lombard AL, Jean-Claude BJ.

J Pharm Biomed Anal. 2011 Nov 1;56(3):592-9. doi: 10.1016/j.jpba.2011.06.013. Epub 2011 Jun 24.

PMID:
21764236
20.

Synthesis, characterization and anticancer studies of mixed ligand dithiocarbamate palladium(II) complexes.

Khan H, Badshah A, Murtaz G, Said M, Rehman ZU, Neuhausen C, Todorova M, Jean-Claude BJ, Butler IS.

Eur J Med Chem. 2011 Sep;46(9):4071-7. doi: 10.1016/j.ejmech.2011.06.007. Epub 2011 Jun 15.

PMID:
21724304
21.

ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro.

Amrein L, Rachid Z, Jean-Claude B, Soulières D, Aloyz R, Panasci L.

Leukemia. 2011 Sep;25(9):1512-6. doi: 10.1038/leu.2011.110. Epub 2011 Jun 7. No abstract available.

22.

In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-molecule.

Golabi N, Rachid Z, Qiu Q, Huang Y, Jean-Claude BJ.

Drug Metab Lett. 2011 Apr;5(2):141-9.

PMID:
21457144
23.

Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK.

Larroque-Lombard AL, Todorova M, Qiyu Q, Jean-Claude B.

Chem Biol Drug Des. 2011 May;77(5):309-18. doi: 10.1111/j.1747-0285.2011.01098.x. Epub 2011 Mar 25.

PMID:
21294849
24.

MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1.

Huang Y, Rachid Z, Jean-Claude BJ.

Mol Cancer Res. 2011 Mar;9(3):320-31. doi: 10.1158/1541-7786.MCR-10-0407. Epub 2011 Jan 24.

25.

The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.

Banerjee R, Huang Y, Qiu Q, McNamee JP, Belinsky G, Jean-Claude BJ.

Cell Signal. 2011 Apr;23(4):630-40. doi: 10.1016/j.cellsig.2010.11.014. Epub 2010 Dec 5.

PMID:
21138763
26.

Antineoplastic Activity of New Transition Metal Complexes of 6-Methylpyridine-2-carbaldehyde-N(4)-ethylthiosemicarbazone: X-Ray Crystal Structures of [VO(2)(mpETSC)] and [Pt(mpETSC)Cl].

Elsayed SA, El-Hendawy AM, Mostafa SI, Jean-Claude BJ, Todorova M, Butler IS.

Bioinorg Chem Appl. 2010:149149. doi: 10.1155/2010/149149. Epub 2010 Jul 1.

27.

Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.

Watt HL, Rachid Z, Jean-Claude BJ.

J Neurooncol. 2010 Dec;100(3):345-61. doi: 10.1007/s11060-010-0196-7. Epub 2010 May 14.

PMID:
20467786
28.

Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.

MacPhee M, Rachid Z, Todorova M, Qiu Q, Belinsky G, Jean-Claude BJ.

Invest New Drugs. 2011 Oct;29(5):833-45. doi: 10.1007/s10637-010-9431-5. Epub 2010 Apr 29.

PMID:
20428924
29.

Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.

Todorova MI, Larroque AL, Dauphin-Pierre S, Fang YQ, Jean-Claude BJ.

Mol Cancer Ther. 2010 Apr;9(4):869-82. doi: 10.1158/1535-7163.MCT-09-0673. Epub 2010 Mar 30.

30.

The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.

Banerjee R, Huang Y, McNamee JP, Todorova M, Jean-Claude BJ.

J Pharmacol Exp Ther. 2010 Jul;334(1):9-20. doi: 10.1124/jpet.109.160085. Epub 2010 Mar 26.

31.

Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5.

Larroque-Lombard AL, Todorova M, Golabi N, Williams C, Jean-Claude BJ.

J Med Chem. 2010 Mar 11;53(5):2104-13. doi: 10.1021/jm9016043.

PMID:
20151639
32.

Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.

Rachid Z, Macphee M, Williams C, Todorova M, Jean-Claude BJ.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5505-9. doi: 10.1016/j.bmcl.2009.05.060. Epub 2009 May 20.

PMID:
19665377
33.

Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.

Heravi M, Rachid Z, Goudarzi A, Schlisser A, Jean-Claude BJ, Radzioch D, Muanza TM.

Anticancer Drugs. 2009 Sep;20(8):659-67. doi: 10.1097/CAD.0b013e32832cb8bc.

PMID:
19581798
34.

Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class.

Qiu Q, Larroque AL, Gibbs B, Fang Y, Lakhrissi Y, Soucy JP, Mzengeza S, Rachid Z, Jean-Claude BJ.

Drug Metab Lett. 2009 Jan;3(1):1-9.

PMID:
19356110
35.

Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.

Barchéchath S, Williams C, Saade K, Lauwagie S, Jean-Claude B.

Chem Biol Drug Des. 2009 Apr;73(4):380-7. doi: 10.1111/j.1747-0285.2009.00786.x.

PMID:
19291100
36.

Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.

Katsoulas A, Rachid Z, McNamee JP, Williams C, Jean-Claude BJ.

Mol Cancer Ther. 2008 May;7(5):1033-43. doi: 10.1158/1535-7163.MCT-07-0179.

37.

Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase.

Larroque AL, Peori B, Williams C, Fang YQ, Qiu Q, Rachid Z, Jean-Claude BJ.

Chem Biol Drug Des. 2008 Apr;71(4):374-9. doi: 10.1111/j.1747-0285.2008.00638.x.

PMID:
18324926
38.

Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties.

Rachid Z, Katsoulas A, Williams C, Larroque AL, McNamee J, Jean-Claude BJ.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4248-53. Epub 2007 May 24.

PMID:
17572088
39.

Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.

Rachid Z, Brahimi F, Qiu Q, Williams C, Hartley JM, Hartley JA, Jean-Claude BJ.

J Med Chem. 2007 May 31;50(11):2605-8. Epub 2007 May 2.

PMID:
17472358
41.

The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.

Qiu Q, Domarkas J, Banerjee R, Merayo N, Brahimi F, McNamee JP, Gibbs BF, Jean-Claude BJ.

Clin Cancer Res. 2007 Jan 1;13(1):331-40.

42.

Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.

Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee JP, Jean-Claude BJ.

Anticancer Drugs. 2007 Feb;18(2):171-7.

PMID:
17159603
43.

Non-operative management of adult blunt splenic injuries.

Yang J, Gao JM, Jean-Claude B.

Chin J Traumatol. 2006 Aug;9(4):246-8.

PMID:
16848999
44.

The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).

Domarkas J, Dudouit F, Williams C, Qiyu Q, Banerjee R, Brahimi F, Jean-Claude BJ.

J Med Chem. 2006 Jun 15;49(12):3544-52.

PMID:
16759097
45.

The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo.

Merayo N, Rachid Z, Qiu Q, Brahimi F, Jean-Claude BJ.

Anticancer Drugs. 2006 Feb;17(2):165-71.

PMID:
16428934
46.

Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.

Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ.

Biochem Pharmacol. 2005 Aug 15;70(4):511-9.

PMID:
15982640
47.

Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.

Katsoulas A, Rachid Z, Brahimi F, McNamee J, Jean-Claude BJ.

Leuk Res. 2005 Jun;29(6):693-700. Epub 2005 Jan 30.

PMID:
15863211
48.

Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl.

Katsoulas A, Rachid Z, Brahimi F, McNamee J, Jean-Claude BJ.

Leuk Res. 2005 May;29(5):565-72. Epub 2005 Jan 26.

PMID:
15755509
49.

Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status.

Rachid Z, Brahimi F, Domarkas J, Jean-Claude BJ.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1135-8.

PMID:
15686928
50.

[Combi-molecules: a global approach towards better chemoselectivity and chemosensitivity].

Matheson S, Qiu Q, Brahimi F, Dudouit F, Banerjee R, Rachid Z, Jean-Claude BJ.

Bull Cancer. 2004 Dec;91(12):911-5. French.

Supplemental Content

Loading ...
Support Center